Innovative Biotech Solutions
Transforming Medicine with Advanced Therapies
At Beijing Biotech, we integrate cutting-edge science with clinical application to revolutionize the treatment of complex medical conditions.
About Us
Leading the Way in Biotech Innovation and Collaboration
Beijing Biotech pioneers advanced cellular immunotherapies and regenerative medicine, reinforcing its position at the forefront of global biotech innovation through collaborations across the medical and research sectors.
NK Cell Therapy & CAR-NK Cell Therapy in China
For families exploring advanced Immunotherapy for Cancer, Cell-based treatments like NK Cell Therapy, CAR-NK, and CAR-T Therapy can sound similar – yet they differ in targets, safety monitoring, and availability.
This page explains the basics in clear language, outlines a typical treatment journey in China, and shows how to compare programs in major medical hubs such as Beijing, Shanghai, Tianjin, Suzhou, Guangzhou, and Chengdu.
Beijing Biotech is proudly based in Beijing, China
We manufacture and support cellular therapy workflows across multiple modalities (program-dependent) and collaborate with hospitals in China and with leading hospitals globally. Clinical decisions, eligibility, and treatment delivery are always made by the treating hospital’s licensed physicians.
Learn how NK Cell Therapy and CAR-NK therapy
Delivered in China for cancer treatment, including options in: Beijing, Shanghai, Guangzhou, and Chengdu.
This guide explains eligibility criteria for international patients, NK cell infusion timelines and processes, GMP manufacturing standards, and how to interpret CAR-NK success rates and safety data.
Explore CAR-NK vs CAR-T comparisons, potential side effects, hospital options in Beijing, cost and price factors, and available clinical trials for leukemia and B-cell lymphoma—while understanding how Beijing Biotech coordinates care from consultation to treatment completion.
What matters most when you evaluate an NK program:
Cell source
Patient-derived (autologous) vs donor-derived (allogeneic).
Manufacturing method
Activation and expansion approach, release testing, and documentation.
Treatment setting
Registered clinical trial vs hospital program.
Monitoring plan
Who manages fever, low blood pressure, infections, and lab changes.
Why Choose Beijing Biotech?
1.Innovative Therapies
2.Global Collaboration
3.Patient-Centric Support
4.Research Excellence
Hear From Our Patients
James Carter
Melanoma
Beijing Biotech delivered outstanding support and clinical solutions that completely changed my treatment experience. Their expertise is unparalleled.
Multiple Myeloma